Browsing by Author Ruby, E

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 6 of 6
TitleAuthor(s)Issue DateViews
 
Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients
Proceeding/Conference:Hepatology
Sulkowski, MSAgarwal, KFung, SKYuen, RMFMa, XLLalezari, JPNguyen, TTBae, HSSchiff, ERHassanein, THann, HWLElkhashab, MDieterich, DTKwo, PYNahass, RRamji, APark, JSRavendhran, NChan, SWeilert, FHan, SHBAyoub, WSGane, EJJacobson, IMBennett, MBonacini, MZayed, HAlves, KHuey, VHuang, QRuby, EQiang, DMKnox, SColonno, R
2019
54
 
Final results of a phase 1b 28-day study of ABI-H0731, a novel core inhibitor, in non-cirrhotic viremic subjects with chronic hepatitis B
Journal:Hepatology
Yuen, RMFAgarwal, KGane, EJSchwabe, .CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RConnelly, ECai, DWHuang, QColonno, RLopatin, UA
2018
50
 
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Proceeding/Conference:Journal of Hepatology
Ma, XLLalezari, JNguyuen, TBae, HoSchiff, ERFung, SYuen, RMFHassanein, THann, HWElkhashab, MDieterich, DSulkowski, MKwo, PNahass, RAgarwal, KRamji, APark, JRavendhran, NChan, SWeilert, FHan, SHAyoub, WGane, EJacobson, IBennett, MHuang, QYan, RHuey, VRuby, ELiaw, SColonno, RLopatin, U
2019
74
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
110
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
31
 
The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Yuen, RMFAgarwal, KGane, EJNguyen, TTHassanein, TKim, DJAlves, KZayed, HQiang, DMRuby, EEvanchik, MHuang, QKnox, SColonno, Ron behalf of ABI-H2158 Study Team
2019
29
Showing results 1 to 6 of 6